NewLimit, the longevity biotech startup co-founded by Coinbase CEO Brian Armstrong, has raised $435 million in Series C funding to move its first age-reprogramming drug toward human trials. Founders Fund led the round, with new investors Thrive Capital, Greenoaks and Quiet Capital joining existing backers Kleiner Perkins, Abstract, Nat Friedman and Daniel Gross, Valor Equity Partners, Eli Lilly Ventures and Human Capital.
Founders Fund Leads $435M Round as Valuation Hits $3.1B
Announced on June 2, the funding round lifts NewLimit's valuation to $3.1 billion — more than triple its level last year, according to The Wall Street Journal. The company plans to use the proceeds to initiate human clinical trials for its first aging reprogramming drug in 2025. “Following breakthrough results, we’re bringing longevity medicine to human trials,” NewLimit said.
Epigenetic Reprogramming Targets Liver Aging
NewLimit focuses on epigenetic reprogramming, a method that restores youthful function in old cells by changing cell behavior without altering the DNA code. Its first program targets the liver: early research showed that the therapy prompted aged human liver cells to display signs of younger functionality. The company will test this approach in its first human trial.
Armstrong’s Bet Beyond Crypto
Founded in 2021 by Armstrong, former GV partner Blake Byers and computational biologist Jacob Kimmel (CEO), NewLimit has become one of Armstrong’s most high-profile projects outside Coinbase. Meanwhile, crypto.news reported that Coinbase used AI to cut account restriction resolution times by 90%, and Armstrong has listed AI tools, stablecoins and tokenization among key finance upgrades.
No Approved Product Yet, But Capital Accelerates Timeline
With $435 million in new capital, NewLimit joins the ranks of the best-funded private longevity startups. The company still has no approved product on the market. It initially believed bringing an aging drug to human trials would take over a decade, but recent scientific results allowed it to move faster. The funding will support expansion across liver, immune, metabolic and vascular programs, giving Armstrong’s biotech venture a larger role in the growing longevity medicine market.